Skip to main content
. Author manuscript; available in PMC: 2023 Sep 8.
Published in final edited form as: Sci Transl Med. 2023 Feb 8;15(682):eabn5649. doi: 10.1126/scitranslmed.abn5649

Fig. 6. Pre-existing intratumoral T cells facilitate D+C antitumor response against gliomas.

Fig. 6.

(A) Survival of CT-VIII tumor mice (n=10/group) treated with control or D+C therapy with or without FTY as indicated. (B) FC analysis of CD8+ T cells in day 0 blood (pre-tumor), day 6 blood (post-tumor), day 13 blood and brain (post-tumor) from CT-VIII tumor-bearing mice (n=4/group) treated as in 5A. Data are mean ± SEM. (C-F) Representative IF images of tumor sections from CT-VIII tumors (n=4/group), treated as in 5A and harvested 7-d post-therapy, stained for DAPI (nucleus, blue), CD8+ T cells (red), and Ki-67 (green) proliferation marker. The CD8+Ki-67+ cell frequency by QMIF analysis post indicated treatment is presented. Scale bar: 200 μm. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.